PRLD

Prelude Therapeutics Inc Q3 Loss Decreases, Beats Estimates

(RTTNews) - Prelude Therapeutics Inc (PRLD) revealed Loss for third quarter that decreased from the same period last year and beat the Street estimates.

The company's bottom line came in at -$19.73 million, or -$0.26 per share. This compares with -$32.27 million, or -$0.43 per share, last year.

Analysts on average had expected the company to earn -$0.35 per share. Analysts' estimates typically exclude special items.

The company's revenue for the period rose 116.7% to $6.50 million from $3.00 million last year.

Prelude Therapeutics Inc earnings at a glance (GAAP) :

-Earnings: -$19.73 Mln. vs. -$32.27 Mln. last year. -EPS: -$0.26 vs. -$0.43 last year. -Revenue: $6.50 Mln vs. $3.00 Mln last year.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Data is currently not available

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.